Therapeutic Orientation Test in Thrombotic Microangiopathy

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Feb 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new test aimed at improving the diagnosis of Haemolytic and Uraemic Syndrome (HUS), a serious condition that affects the blood and kidneys. The researchers want to see if this test can help determine if a specific part of the immune system, called the complement system, is involved in causing the disease. The test looks for certain signs on the surface of blood vessel cells when comparing them to normal blood samples. This information could help doctors decide the best treatment, especially with a medication called Eculizumab, which is more effective when started early in the course of the disease.

To participate in this study, individuals must have certain symptoms related to Thrombotic Microangiopathy (TMA), such as low blood platelets, signs of hemolysis (breaking down of red blood cells), and kidney problems. Some people will not be eligible, including those who have received certain treatments recently or are pregnant. If eligible, participants will have their blood tested, and doctors will monitor their health to see how the test results relate to their condition over time. This trial is currently recruiting participants of all ages and genders, and patients interested in joining should discuss it with their healthcare provider to see if it's right for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• TMA with:
• • mechanic haemolytic anemia, undetectable haptoglobin, LDH\>1.5\*LNS
• • thrombopenia
• • acute kidney injury TMA on native kidney or in post-transplantation.
• Exclusion Criteria:
• • DIVC patients
• • plasma exchange during 1 month before sample collection
• • treatment by Eculizumab before sample collection
• • no consent
• • not beneficiary of a social security
• • pregnancy or breastfeeding
• • patient Under guardianship